Drug persistency of cholinesterase inhibitors for patients with dementia of Alzheimer type in Korea

Archives of Pharmacal Research

Volumn 38, Issue 6, 2015, Pages 1255-1262

  Ahn, So Hyeon ^a,b   Choi, Nam Kyong ^b,c   Kim, Ye Jee ^a,b   Seong, Jong Mi ^a,b   Shin, Ju Young ^a,b   Jung, Sun Young ^a,b   Park, Byung Joo ^a,b  

^a Korea Institute of Drug Safety and Risk Management   (South Korea)

^b Seoul National University   (South Korea)

^c Seoul National University Hospital   (South Korea)

Author keywords

Cholinesterase inhibitors; Dementia, Alzheimer type; Elderly; Medication persistence; Pharmacoepidemiology

Indexed keywords

DONEPEZIL; GALANTAMINE; RIVASTIGMINE; CHOLINESTERASE INHIBITOR;

AGED; ALZHEIMER DISEASE; ARTICLE; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GROUPS BY AGE; HUMAN; KOREA; MALE; OSTEOARTHRITIS; PRESCRIPTION; PRIMARY MEDICAL CARE; RURAL AREA; VERY ELDERLY; AGE; MEDICATION COMPLIANCE; PHARMACOEPIDEMIOLOGY; PRIMARY HEALTH CARE; RURAL POPULATION; SEX DIFFERENCE; SOUTH KOREA; STATISTICS AND NUMERICAL DATA; SURVIVAL ANALYSIS; URBAN POPULATION;

AGE FACTORS; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; PHARMACOEPIDEMIOLOGY; PRIMARY HEALTH CARE; REPUBLIC OF KOREA; RURAL POPULATION; SEX FACTORS; SURVIVAL ANALYSIS; URBAN POPULATION;

EID: 84930864988     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-014-0500-8     Document Type: Article

References (33)

1. Abughosh, S.M., and S.J. Kogut. 2008. Comparison of persistence rates of acetylcholine-esterase inhibitors in a state Medicaid program. Patient Preference and Adherence 2: 79-85.
2. Alzheimer's Association. 2010. 2010 Alzheimer's disease facts and figures. Alzheimer's & dementia 6: 158-194.
3. Alzheimer's Disease International. 2012. World Alzheimer report 2012. London: Alzheimer's Disease International.
4. Amuah, J.E., D.B. Hogan, M. Eliasziw, A. Supina, P. Beck, W. Downey, and C.J. Maxwell. 2010. Persistence with cholinesterase inhibitor therapy in a population-based cohort of patients with Alzheimer's disease. Pharmacoepidemiology and Drug Safety 19: 670-679.
5. Brewer, L., K. Bennett, C. McGreevy, and D. Williams. 2013. A population-based study of dosing and persistence with anti-dementia medications. European Journal of Clinical Pharmacology 69: 1467-1475.
6. Callahan, C.M., H.C. Hendrie, and W.M. Tierney. 1995. Documentation and evaluation of cognitive impairment in elderly primary care patients. Annals of Internal Medicine 122: 422-429.
7. Cho, M., G. Kim, M. Kim, M. Kim, B. Kim, and S. Kim. 2008. Nationwide study on the prevalence of dementia in Korean elders. Seoul: Seoul National University Hospital.
8. Cummings, J.L., J.C. Frank, D. Cherry, N.D. Kohatsu, B. Kemp, L. Hewett, and B. Mittman. 2002. Guidelines for managing Alzheimer's disease: Part II. Treatment. American Family Physician 65: 2525-2534.
9. Doody, R.S., D.S. Geldmacher, B. Gordon, C.A. Perdomo, and R.D. Pratt. 2001. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Archives of Neurology 58: 427-433.
10. Dybicz, S.B., D.J. Keohane, W. Erwin, T. Mcrae, and S.N. Shah. 2006. Patterns of cholinesterase-inhibitor use in the nursing home setting: a retrospective analysis. The American Journal of Geriatric Pharmacotherapy 4: 154-160.
11. Fillit, H., and J. Hill. 2005. Economics of dementia and pharmacoeconomics of dementia therapy. The American Journal of Geriatric Pharmacotherapy 3: 39-49.
12. Gauthier, S., M. Emre, M.R. Farlow, R. Bullock, G.T. Grossberg, and S.G. Potkin. 2003. Strategies for continued successful treatment of Alzheimer's disease: switching cholinesterase inhibitors. Current Medical Research and Opinion 19: 707-714.
13. Herrmann, N., S.S. Gill, C.M. Bell, G.M. Anderson, S.E. Bronskill, K.I. Shulman, H.D. Fischer, K. Sykora, H.S. Shi, and P.A. Rochon. 2007. A population-based study of cholinesterase inhibitor use for dementia. Journal of the American Geriatrics Society 55: 1517-1523.
14. Johannsen, P. 2004. Long-term cholinesterase inhibitor treatment of Alzheimer's disease. CNS drugs 18: 757-768.
15. Johannsen, P., E. Salmon, H. Hampel, Y. Xu, S. Richardson, S. Qvitzau, and R. Schindler. 2006. Assessing therapeutic efficacy in a progressive disease. CNS Drugs 20: 311-325.
16. Joo, K., H. Kim, S. Lee, and H. Min. 1996. A Comparative study on medical utilization between Urban and Rural Korea. Korean Journal of Preventive Medicine 29: 311-330.
17. Kang, S.J., S.J. Yoon, J.H. Jeong, and D.L. Na. 2001. Time interval between the recognition of dementia symptom and the first hospital visit in Alzheimer's disease. Journal of Korean Neurological Association 19: 62-64.
18. Korean Dementia Association. 2006. Dementia: A clinical approach. Seoul: Academia.
19. Lee, D.W., Y.S. Huh, and K.W. Kim. 2009. Evidence-based treatment of Alzheimer's disease. Journal of the Korean Medical Association 52: 417-425.
20. Lee, K.S., D.W. Lee, J.Y. Lee, H.K. Cheong, K.R. Kim, J.H. Choi, B.H. Oh, and C.H. Hong. 2006. Analysis of current status of management for dementia between city and country health center. Journal of Korean Geriatric Psychiatry 10: 84-89.
21. Mauskopf, J.A., C. Paramore, W.C. Lee, and E.H. Snyder. 2005. Drug persistency patterns for patients treated with rivastigmine or donepezil in usual care settings. Journal of Managed Care Pharmacy 11: 231-251.
22. Mucha, L., S.S. Wang, B. Cuffel, T. Mcrae, T.L. Mark, and M. Del Valle. 2008. Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer's disease. Journal of Managed Care Pharmacy 14: 451-461.
23. O'connor, D., P. Pollitt, J. Hyde, C. Brook, B. Reiss, and M. Roth. 1988. Do general practitioners miss dementia in elderly patients? British Medical Journal 297: 1107-1110.
24. Park, B., J. Sung, K. Park, S. Seo, and S. Kim. 2003. Report of the evaluation for validity of discharged diagnoses in Korean Health Insurance database, 19-52. Seoul: Seoul National University.
25. Rabins, P., D. Blacker, B. Rovner, T. Rummans, L. Schneider, P. Tariot, D. Blass, J. Mcintyre, S. Charles, and D. Anzia. 2007. American Psychiatric Association practice guideline for the treatment of patients with Alzheimer's disease and other dementias. Arlington: American Psychiatirc Association.
26. Rountree, S.D., A. Atri, O.L. Lopez, and R.S. Doody. 2013. Effectiveness of antidementia drugs in delaying Alzheimer's disease progression. Alzheimer's & Dementia 9: 338-345.
27. Sabaté, E. 2003. Adherence to long-term therapies: evidence for action. Geneva: World Health Organization.
28. Sikka, R., F. Xia, and R.E. Aubert. 2005. Estimating medication persistency using administrative claims data. The American Journal of Managed Care 11: 449-457.
29. Suh, D.C., S.K. Thomas, E. Valiyeva, S. Arcona, and L. Vo. 2005. Drug persistency of two cholinesterase inhibitors. Drugs and Aging 22: 695-707.
30. Suh, G.H. 2007. Drug therapy for Alzheimer's disease. Journal of the Korean Medical Association 50: 369-374.
31. Thompson, S., K.L. Lanctôt, and N. Herrmann. 2004. The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease. Expert Opinion on Drug Safety 3: 425-440.
32. Wimo, A., B. Winblad, and L. Jonsson. 2007. An estimate of the total worldwide societal costs of dementia in 2005. Alzheimer's & Dementia 3: 81-91.
33. Winblad, B., and V. Jelic. 2004. Long-term treatment of Alzheimer disease: Efficacy and safety of acetylcholinesterase inhibitors. Alzheimer Disease and Associated Disorders 18(Suppl 1): S2-S8.